ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,901 to 2,920 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Absorb BVS vs XIENCE: Number of Participants With Target Lesion Revascularization (TLR)38 of 1,255

24 of 1,273

1.1 points

-0.1 to 2.4

2,528NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Ischemia Driven TLR (ID-TLR)37 of 1,255

24 of 1,273

1.1 points

-0.1 to 2.3

2,528NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Death (Cardiac, Vascular, Non-cardiovascular)16 of 1,255

15 of 1,273

0.1 points

-0.8 to 1.0

2,528NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Target Vessel Myocardial Infarction (TV-MI)75 of 1,255

58 of 1,273

1.4 points

-0.3 to 3.2

2,528NCT02173379

Absorb IV Randomized Controlled Trial

Intervention - Aim 2 vs Control - Aim 2: Number of Patients Who Receive Contraception by Six Months Postpartum595 of 1,461

436 of 1,067

-0.1 points

-4.0 to 3.7

2,528NCT04092530

Linking Inter-professional Newborn and Contraception Care

Obicetrapib 10mg vs Placebo: deaths from any cause19 of 1,685

12 of 843

-0.3 points

-1.4 to 0.6

2,528NCT05142722

Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

Obicetrapib 10mg vs Placebo: serious adverse events211 of 1,685

117 of 843

-1.4 points

-4.3 to 1.4

2,528NCT05142722

Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

Absorb BVS vs XIENCE: TLF at 1-year, Non-inferiority Against the Control98 of 1,254

82 of 1,272

1.4 points

-0.6 to 3.4

2,526NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Rehospitalization277 of 1,254

289 of 1,271

-0.6 points

-3.9 to 2.6

2,525NCT02173379

Absorb IV Randomized Controlled Trial

Darbepoetin Alfa vs Placebo: deaths from any cause1,273 of 1,685

657 of 833

-3.3 points

-6.7 to 0.2

2,518NCT00858364

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Darbepoetin Alfa vs Placebo: serious adverse events524 of 1,685

259 of 833

0.0 points

-3.9 to 3.8

2,518NCT00858364

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Intervention - Aim 2 vs Control - Aim 2: Number of Patients Who Receive Contraception by Two Months Postpartum474 of 1,497

339 of 1,021

-1.5 points

-5.3 to 2.2

2,518NCT04092530

Linking Inter-professional Newborn and Contraception Care

BDA MDI (PT027) 160/180 μg vs AS MDI (PT007) 180 µg: deaths from any cause2 of 1,257

1 of 1,259

0.1 points

-0.3 to 0.5

2,516NCT05505734

A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma

Absorb BVS vs XIENCE: Angina at 1-year, Non-inferiority Against the Control459 of 1,248

494 of 1,265

-2.3 points

-6.1 to 1.5

2,513NCT02173379

Absorb IV Randomized Controlled Trial

EHR-based Clinician Jumpstart vs Usual Care: Intensity of Care: ICU Admissions 30 Days336 of 1,255

348 of 1,257

-0.9 points

-4.4 to 2.6

2,512NCT04281784

Project to Improve Communication About Serious Illness--Hospital Study: Pragmatic Trial (Trial 1)

EHR-based Clinician Jumpstart vs Usual Care: deaths from any cause70 of 1,255

64 of 1,257

0.5 points

-1.3 to 2.3

2,512NCT04281784

Project to Improve Communication About Serious Illness--Hospital Study: Pragmatic Trial (Trial 1)

EHR-based Clinician Jumpstart vs Usual Care: Intensity of Care: Hospital Readmissions 30 Days265 of 1,255

251 of 1,257

1.1 points

-2.0 to 4.3

2,512NCT04281784

Project to Improve Communication About Serious Illness--Hospital Study: Pragmatic Trial (Trial 1)

Anti-pseudomonal Cephalosporin vs Anti-pseudomonal Penicillin: Major Adverse Kidney Events Within 14 Days (MAKE14)124 of 1,214

114 of 1,297

1.4 points

-0.9 to 3.7

2,511NCT05094154

Effect of Antibiotic Choice On ReNal Outcomes (ACORN)

Anti-pseudomonal Cephalosporin vs Anti-pseudomonal Penicillin: deaths from any cause104 of 1,214

106 of 1,297

0.4 points

-1.8 to 2.6

2,511NCT05094154

Effect of Antibiotic Choice On ReNal Outcomes (ACORN)

Vaccine vs Placebo: deaths from any cause1 of 1,253

11 of 1,251

-0.8 points

-1.5 to -0.3

2,504NCT00865566

Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=146"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=146

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02173379-baba8cde",
        "title": "Absorb BVS vs XIENCE: Number of Participants With Target Lesion Revascularization (TLR)",
        "summary": "38 of 1255 against 24 of 1273; risk difference 1.1 points, 95% interval -0.1 to 2.4; NCT02173379, Absorb IV Randomized Controlled Trial",
        "record": "/library/comparisons/NCT02173379-baba8cde",
        "nct_id": "NCT02173379",
        "kind": "outcome",
        "participants": 2528,
        "risk_difference": {
          "value": 0.011425781555631363,
          "lower": -0.0007441408843121729,
          "upper": 0.024035205338199007
        },
        "group_1": "38 of 1,255",
        "group_2": "24 of 1,273",
        "difference": "1.1 points",
        "interval": "-0.1 to 2.4",
        "trial_title": "Absorb IV Randomized Controlled Trial"
      },
      {
        "id": "NCT02173379-bea2e9c0",
        "title": "Absorb BVS vs XIENCE: Number of Participants With Ischemia Driven TLR (ID-TLR)",
        "summary": "37 of 1255 against 24 of 1273; risk difference 1.1 points, 95% interval -0.1 to 2.3; NCT02173379, Absorb IV Randomized Controlled Trial",
        "record": "/library/comparisons/NCT02173379-bea2e9c0",
        "nct_id": "NCT02173379",
        "kind": "outcome",
        "participants": 2528,
        "risk_difference": {
          "value": 0.010628968806627379,
          "lower": -0.0014595449360682716,
          "upper": 0.023136081366613992
        },
        "group_1": "37 of 1,255",
        "group_2": "24 of 1,273",
        "difference": "1.1 points",
        "interval": "-0.1 to 2.3",
        "trial_title": "Absorb IV Randomized Controlled Trial"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=147",
  "request_id": "nIWAxE1DhHMsH20L"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?